| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/14/2009 | EP1223978B1 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses |
| 01/14/2009 | EP1210724B1 Method of determining etch endpoint using principal components analysis of optical emission spectra |
| 01/14/2009 | EP1204753B1 Invasive bacteria based viral vaccines |
| 01/14/2009 | EP1187918B2 Tek antagonists |
| 01/14/2009 | EP1183049B1 Modification of biological elements |
| 01/14/2009 | EP1051189B2 Vaccine formulation containing a polycation as an adjuvant and sugar-alcohols and low concentrations of anorganic ions |
| 01/14/2009 | EP0724594B1 Regulation of transcription factor, nf-il6/lap |
| 01/14/2009 | CN101346463A Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
| 01/14/2009 | CN101346395A Anti-IL-6 antibodies preventing the binding of IL-6 complexed with il-6Ralpha to GP130 |
| 01/14/2009 | CN101346394A TGF-beta binding compositions |
| 01/14/2009 | CN101346153A Immunoglobulin G (IGG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IGGS |
| 01/14/2009 | CN101346152A Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| 01/14/2009 | CN101346137A Combination comprising combretastatin and anticancer agents |
| 01/14/2009 | CN101343623A Hybrid tumor, antihuman bladder cancer monoantibody and guide medicament, and bladder cancer diagnosis agent |
| 01/14/2009 | CN101343324A Method for the inhibition of human TNF alpha activity |
| 01/14/2009 | CN101343323A Anti-interleukins-8 antibody |
| 01/14/2009 | CN101343320A Anti-vibrio parahaemolyticus chicken yolk antibody, preparation method and application thereof |
| 01/14/2009 | CN101343319A Anti-dengue virus E protein monoclone antibody, preparation method and uses thereof |
| 01/14/2009 | CN101343251A Thrombopoietin mimetics |
| 01/14/2009 | CN101343250A Thrombopoietin mimetics |
| 01/14/2009 | CN101342368A Antigenized antibody vaccine for foot-and-mouth disease |
| 01/14/2009 | CN101342367A Edwardsiella tarda attenuated live vaccine |
| 01/14/2009 | CN101342169A Thrombopoietin mimetics |
| 01/14/2009 | CN101342148A Quick-effective antimicrobial, anti-inflammation, antiviral hyperconcentrated natural allicin tablet and preparation method thereof |
| 01/14/2009 | CN100451109C Recombinant herpes simplex virus type 2 and its preparing method and use |
| 01/14/2009 | CN100450552C Vaccine for diabetes in type I, and constructing method |
| 01/14/2009 | CN100450551C Recombinated adeno-associated virus genes vaccine for prevention and cure of Alzheimer disease and use thereof |
| 01/13/2009 | US7476728 Flea GABA receptor subunit nucleic acid molecules |
| 01/13/2009 | US7476722 Chromatography separation using apatite; protein being purified can comprise at least one constant antibody immunoglobulin domain |
| 01/13/2009 | US7476721 Modified cytokines for use in cancer therapy |
| 01/13/2009 | US7476720 Rat neurotrophic factor receptor, GFR α-4 |
| 01/13/2009 | US7476719 Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof |
| 01/13/2009 | US7476669 Immobilization of taxane; anticancer, antitumor agents |
| 01/13/2009 | US7476535 Tyrosinase-related gene (TRP2) protein comprising human leukocyte antigen cytotoxic binding recognition points for identifying modulators for diagnosis, prevention and treatment of cancer ; immunotherapy |
| 01/13/2009 | US7476530 Vaccines against Mycobacterium for mouth administering |
| 01/13/2009 | US7476391 Attenuated pasteurella for use as tool in developing bactericidal agents; immunotherapy |
| 01/13/2009 | US7476390 Polypeptides and polynucleotides useful in methods of inducing immune response against flaviviruses, including dengue viruses |
| 01/13/2009 | US7476389 Papillomavirus vaccines |
| 01/13/2009 | US7476387 Chimeric empty viral-like particles derived from the infectious bursal disease virus (IBDV), process for their production and applications |
| 01/13/2009 | US7476386 Mixed lipopeptide micelles for inducing an immune response |
| 01/13/2009 | US7476385 Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1 |
| 01/13/2009 | US7476384 Death domain containing receptor 4 antibody and methods |
| 01/13/2009 | US7476383 Antiproliferative agent; induction apoptosis; antitumor agents |
| 01/13/2009 | CA2615372A1 Influenza virus-like particles (vlps) comprising hemagglutinin |
| 01/13/2009 | CA2397785C The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 01/13/2009 | CA2263750C Use of a melanoma differentiation associated gene (mda-7) for reversing a cancerous phenotype |
| 01/13/2009 | CA2233932C Vaccines against infections caused by yf virus; yf infectious cdna, method for producing a recombinant yf virus from the yf infectious cdna and plasmids to assemble the yf infectious cdna |
| 01/13/2009 | CA2105534C Tnf ligands |
| 01/08/2009 | WO2009006638A2 Peptides facilitating retrograde transport and their uses |
| 01/08/2009 | WO2009006579A1 Peptide-polymer conjugates |
| 01/08/2009 | WO2009006420A2 Vaccine production for pathogenic bird viral diseases |
| 01/08/2009 | WO2009006359A2 Anti- mcp-1 antibodies, compositions, methods and uses |
| 01/08/2009 | WO2009006301A2 Protein stabilization |
| 01/08/2009 | WO2009006141A2 Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
| 01/08/2009 | WO2009006112A1 Mdl-1 uses |
| 01/08/2009 | WO2009005870A2 Products for prophylaxis and/or treatment of viral diseases and method of making and using same |
| 01/08/2009 | WO2009005813A1 Modulators of axl for use in treating bone disorders |
| 01/08/2009 | WO2009005726A1 Antigen binding proteins that bind par-2 |
| 01/08/2009 | WO2009005673A1 Anti-igf1r |
| 01/08/2009 | WO2009005142A1 Method for diagnosis of malignancy of gastrointestinal stromal tumor whose primary lesion is in stomach |
| 01/08/2009 | WO2009005040A1 Pseudomonas aeruginosa outer membrane protein pa4710 |
| 01/08/2009 | WO2009004900A1 Ubiquinone-containing immunoadjuvant |
| 01/08/2009 | WO2009004842A1 Vaccine for swine edema disease |
| 01/08/2009 | WO2009004822A1 ANTI-Muc17 ANTIBODY |
| 01/08/2009 | WO2009004641A2 Adaptation of pitman moore strain of rabies virus to primary chick embryo fibroblast cell cultures |
| 01/08/2009 | WO2009004569A1 Use of intranasally administered pidotimod to enhance antigen-specific humoral and cell-mediated immune response |
| 01/08/2009 | WO2009004094A2 Compounds and methods for the treatment of renal disease |
| 01/08/2009 | WO2009004002A1 Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli |
| 01/08/2009 | WO2009003975A1 Antibodies against human cytomegalovirus (hcmv) |
| 01/08/2009 | WO2009003905A2 Prognostic method for the determination of the suitability of biopharmaceutical treatment |
| 01/08/2009 | WO2009003889A2 Immunogenic analogues of rankl |
| 01/08/2009 | WO2009003497A1 Diagnostic composition and method for the detection of a trichinella infection |
| 01/08/2009 | WO2009003493A2 Mhc multimers, methods for their generation, labeling and use |
| 01/08/2009 | WO2009003492A1 Mhc multimers, methods for their generation, labeling and use |
| 01/08/2009 | WO2009003489A1 CaOU-1 EPITOPE BINDING POLYPEPTIDES |
| 01/08/2009 | WO2009003474A1 The use of monomycolyl glycerol (mmg) as an adjuvant |
| 01/08/2009 | WO2009003425A1 Production of an homogeneous vaccine preparation for cancer treatment |
| 01/08/2009 | WO2009003291A1 Therapeutics and diagnostics for group a streptococci |
| 01/08/2009 | WO2009003274A1 Susceptibility gene for inflammatory bowel disease |
| 01/08/2009 | WO2008144720A3 Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
| 01/08/2009 | WO2008143709A3 Multivalent pneumococcal polysaccharide-protein conjugate composition |
| 01/08/2009 | WO2008140653A9 Humaneered anti-factor b antibody |
| 01/08/2009 | WO2008140579A3 Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| 01/08/2009 | WO2008137915A3 Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 01/08/2009 | WO2008137552A3 Anti-rage antibodies and methods of use thereof |
| 01/08/2009 | WO2008133663A9 Codon modified immunogenic compositions and methods of use |
| 01/08/2009 | WO2008122440A3 Remedy for the treatment of cardio-vascular diseases or disorders |
| 01/08/2009 | WO2008121616A3 Antibodies with decreased deamidation profiles |
| 01/08/2009 | WO2008120202A3 Antibodies, methods and kits for diagnosing and treating melanoma |
| 01/08/2009 | WO2008119567A3 Cross-species-specific cd3-epsilon binding domain |
| 01/08/2009 | WO2008119565A3 Cross-species-specific binding domain |
| 01/08/2009 | WO2008118711A3 Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof |
| 01/08/2009 | WO2008116103A3 Stable antibody formulations |
| 01/08/2009 | WO2008101175A3 Protein formulations containing sorbitol |
| 01/08/2009 | WO2008091659A3 Methods and compositions for predicting and treating drug resistant strains of influenza virus |
| 01/08/2009 | WO2008073509A3 Compositions and methods for treating a neoplasm |
| 01/08/2009 | WO2007143098A8 Hepatocyte growth factor (hgf) binding proteins |
| 01/08/2009 | WO2007117680A3 Methods and compositions for treating bacterial infection |
| 01/08/2009 | WO2007014114A3 Methods for reducing viral load in hiv-1-infected patients |
| 01/08/2009 | US20090013420 Psmcs as Modifiers of the Rb Pathway and Methods of Use |